Cargando…

In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia

Paroxysmal supraventricular tachycardia (PSVT) is a common tachyarrhythmia, and an electrocardiogram is the best tool for making a diagnosis. If Valsalva maneuvers and carotid sinus massage do not give positive results, then the next choice is either adenosine or calcium channel blockers. At this ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Farrukh, Abu Sneineh, Majdi, Patel, Ravi S, Rohit Reddy, Sai, Llukmani, Adiona, Hashim, Ayat, Haddad, Dana R, Gordon, Domonick K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261787/
https://www.ncbi.nlm.nih.gov/pubmed/34268033
http://dx.doi.org/10.7759/cureus.15502
_version_ 1783719070742347776
author Ahmad, Farrukh
Abu Sneineh, Majdi
Patel, Ravi S
Rohit Reddy, Sai
Llukmani, Adiona
Hashim, Ayat
Haddad, Dana R
Gordon, Domonick K
author_facet Ahmad, Farrukh
Abu Sneineh, Majdi
Patel, Ravi S
Rohit Reddy, Sai
Llukmani, Adiona
Hashim, Ayat
Haddad, Dana R
Gordon, Domonick K
author_sort Ahmad, Farrukh
collection PubMed
description Paroxysmal supraventricular tachycardia (PSVT) is a common tachyarrhythmia, and an electrocardiogram is the best tool for making a diagnosis. If Valsalva maneuvers and carotid sinus massage do not give positive results, then the next choice is either adenosine or calcium channel blockers. At this time, adenosine is the drug of choice of treatment. Verapamil and diltiazem are the most commonly used calcium channel blockers (CCBs). This review aimed to compare the efficacy of both drugs in the treatment of PSVT. We utilized the databases PubMed Central and Medline by using keywords: "calcium channel blockers OR adenosine AND supraventricular tachycardia." In the end, we finalized 32 studies, including observational studies, literature reviews, systematic reviews/metanalysis, and randomized control trials. We included articles only in the English language and related to humans. Two authors completed the quality assessment and evaluation of bias according to specific guidelines. Only high-quality studies were included in this systematic review based on the cut-off score of seven or above. Calcium channel blockers have a longer half-life than adenosine and were previously used as the drug of choice in the treatment of PSVT. Calcium channel blockers are safe if given slowly; however, adenosine is safer and useful when an electrocardiogram is uncertain. We compared both drugs in certain aspects and found equal efficacy. Though safer, adenosine was found to have a higher cost and a higher probability of re-initiation arrhythmia compared to calcium channel blockers. 
format Online
Article
Text
id pubmed-8261787
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82617872021-07-14 In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia Ahmad, Farrukh Abu Sneineh, Majdi Patel, Ravi S Rohit Reddy, Sai Llukmani, Adiona Hashim, Ayat Haddad, Dana R Gordon, Domonick K Cureus Cardiology Paroxysmal supraventricular tachycardia (PSVT) is a common tachyarrhythmia, and an electrocardiogram is the best tool for making a diagnosis. If Valsalva maneuvers and carotid sinus massage do not give positive results, then the next choice is either adenosine or calcium channel blockers. At this time, adenosine is the drug of choice of treatment. Verapamil and diltiazem are the most commonly used calcium channel blockers (CCBs). This review aimed to compare the efficacy of both drugs in the treatment of PSVT. We utilized the databases PubMed Central and Medline by using keywords: "calcium channel blockers OR adenosine AND supraventricular tachycardia." In the end, we finalized 32 studies, including observational studies, literature reviews, systematic reviews/metanalysis, and randomized control trials. We included articles only in the English language and related to humans. Two authors completed the quality assessment and evaluation of bias according to specific guidelines. Only high-quality studies were included in this systematic review based on the cut-off score of seven or above. Calcium channel blockers have a longer half-life than adenosine and were previously used as the drug of choice in the treatment of PSVT. Calcium channel blockers are safe if given slowly; however, adenosine is safer and useful when an electrocardiogram is uncertain. We compared both drugs in certain aspects and found equal efficacy. Though safer, adenosine was found to have a higher cost and a higher probability of re-initiation arrhythmia compared to calcium channel blockers.  Cureus 2021-06-07 /pmc/articles/PMC8261787/ /pubmed/34268033 http://dx.doi.org/10.7759/cureus.15502 Text en Copyright © 2021, Ahmad et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Ahmad, Farrukh
Abu Sneineh, Majdi
Patel, Ravi S
Rohit Reddy, Sai
Llukmani, Adiona
Hashim, Ayat
Haddad, Dana R
Gordon, Domonick K
In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title_full In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title_fullStr In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title_full_unstemmed In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title_short In The Line of Treatment: A Systematic Review of Paroxysmal Supraventricular Tachycardia
title_sort in the line of treatment: a systematic review of paroxysmal supraventricular tachycardia
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261787/
https://www.ncbi.nlm.nih.gov/pubmed/34268033
http://dx.doi.org/10.7759/cureus.15502
work_keys_str_mv AT ahmadfarrukh inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT abusneinehmajdi inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT patelravis inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT rohitreddysai inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT llukmaniadiona inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT hashimayat inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT haddaddanar inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia
AT gordondomonickk inthelineoftreatmentasystematicreviewofparoxysmalsupraventriculartachycardia